New chemo drug shows promise for tough testicular cancers
NCT ID NCT02115165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a chemotherapy drug called cabazitaxel in 34 men with advanced testicular cancer that had already been treated with at least two other chemotherapies. The goal was to see if cabazitaxel could shrink tumors, including those that spread to the brain. Cabazitaxel is a newer type of taxane drug that may work better and cause fewer nerve problems than older options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabazitaxel
- What this could lead to
- If it works, this could offer a new treatment option for men with advanced testicular cancer that has stopped responding to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 34 participants. It may not show enough benefit to become a standard treatment, and cabazitaxel can cause side effects like low blood counts and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NONSEMINOMATOUS GERM-CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.